# Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

> **NCT02568683** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 10 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Entospletinib
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT02568683
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-11
- **Primary completion:** 2016-10-03
- **Final completion:** 2017-06-22
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02568683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02568683, "Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02568683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*